Equities

ONWARD Medical NV

ONWARD Medical NV

Actions
Health CareMedical Equipment and Services
  • Price (EUR)5.12
  • Today's Change0.10 / 1.99%
  • Shares traded30.44k
  • 1 Year change+36.90%
  • Beta--
Data delayed at least 15 minutes, as of Nov 08 2024 16:37 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Onward Medical NV, formerly known as GTX Medical BV, is a medical technology company based in the Netherlands. The Company is primarily engaged in developing and commercializing innovative therapies to enable functional recovery for people with spinal cord injury. It develops two technology platforms ARC EX and ARC IM.

  • Revenue in EUR (TTM)0.00
  • Net income in EUR-35.15m
  • Incorporated2015
  • Employees99.00
  • Location
    ONWARD Medical NVSchimmelt 2EINDHOVEN 5611ZXNetherlandsNLD
  • Phone+31 402882830
  • Websitehttps://www.onwd.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
EasyMotionSkin Tec GmbH-100.00bn-100.00bn145.70m17.00------------------------------------------------229.95---214.79------
Agfa Gevaert NV1.13bn-32.00m146.92m5.03k--0.387736.730.1301-0.2057-0.27187.292.450.80562.224.44224,631.90-2.21-4.24-3.10-6.2231.5329.49-2.75-5.601.243.130.306--0.4367-12.1071.20---3.20--
EKF Diagnostics Holdings PLC61.43m5.76m151.26m309.0026.281.8212.552.460.01050.01050.11230.15160.63073.016.99160,728.706.345.207.356.1348.0550.0410.057.913.081,703.500.0175113.68-21.054.34123.28-25.3030.37--
Amplitude Surgical SA106.02m1.53m151.75m428.0099.311.5810.841.430.03180.03182.212.000.38890.53878.20247,707.900.56050.44120.66870.5279.3677.841.441.281.090.69590.5503--5.810.6658-96.11--2.62--
Lumibird SA203.56m7.13m157.27m1.05k19.670.8126.430.77260.35590.35599.148.620.52381.094.05193,497.101.833.132.443.9961.6861.763.505.891.622.470.42870.006.6015.12-37.23-2.4718.34--
Aoti Inc46.11m-8.74m162.39m80.00--11.35--3.52-0.0682-0.06820.35950.11161.563.578.18318,673.90-29.55---41.81--85.76---18.96--2.57-3.080.4812--31.06---191.92------
Meditera Tibbi Mlzm Sny Tcrt AS48.79m-2.34m165.05m769.00--3.20--3.38-0.7247-0.724715.1015.961.013.107.002,468,911.00-4.878.88-5.8410.9142.7643.51-4.829.852.39--0.0333181.79-8.9948.75-77.3815.68----
Stille AB42.03m4.39m165.83m151.0033.822.8625.633.946.336.3360.9474.850.69782.108.494,598,368.007.287.038.708.1949.1743.9310.439.851.127.410.0021.9819.7016.78-2.485.3423.62--
Prim SA227.46m11.43m165.94m901.0014.501.317.430.72950.67170.671713.377.461.141.964.39252,736.005.736.688.348.9038.2838.115.026.431.13--0.13159.389.7710.0051.02-2.1412.86-5.01
Detection Technology Oyj-100.00bn-100.00bn205.18m464.00--2.78----------5.03----------9.34--11.96--47.44--8.223.39--0.0053.455.292.027.55-18.03-14.88-9.55
Medistim ASA46.40m8.62m210.75m152.0024.426.1319.624.545.555.5529.8722.121.130.74617.483,599,204.0021.0522.9325.5328.5279.1278.2518.5820.642.75--0.018175.257.0010.06-8.9112.720.03314.87
Onward Medical NV0.00-35.15m228.50m99.00--8.42-----1.09-1.090.000.60790.00----0.00-66.40-55.70-79.20-61.60-------79,513.95----0.4855---34.62---10.40--32.59--
BICO Group AB194.24m-67.85m228.98m828.00--0.9199--1.18-11.15-15.2031.9241.790.36022.154.472,547,964.00-12.62---14.44--55.70---35.03--2.23-0.57050.397--6.09---1,889.33------
Tristel Plc50.56m7.82m248.61m213.0032.056.3422.424.920.1350.1350.87140.68180.98121.815.74--15.189.3217.7510.7680.0880.7515.4711.093.04--0.1532109.3516.459.8945.469.9910.1319.53
Nyxoah SA5.08m-52.98m301.00m147.00--2.88--59.23-1.72-1.720.1663.040.03660.55692.3034,618.53-38.20-23.73-42.88-25.9861.7562.42-1,042.52-1,469.594.95-45.270.1822--40.99---38.39--100.58--
Data as of Nov 08 2024. Currency figures normalised to ONWARD Medical NV's reporting currency: Euro EUR

Institutional shareholders

17.29%Per cent of shares held by top holders
HolderShares% Held
LSP Advisory BVas of 28 Oct 20243.75m10.84%
E. �hman J :or Fonder ABas of 30 Sep 2024576.50k1.67%
C WorldWide Asset Management Fondsm�glerselskab A/Sas of 31 Dec 2023450.00k1.30%
BNP Paribas Asset Management Belgium SAas of 30 Aug 2024330.80k0.96%
Fondita Fund Management Co. Ltd.as of 30 Sep 2024250.00k0.72%
SEB Investment Management ABas of 30 Aug 2024228.40k0.66%
AXA Investment Managers (Paris) SAas of 31 Oct 2023142.00k0.41%
BNP Paribas Asset Management Europe SASas of 29 Nov 2023113.70k0.33%
DNB Asset Management ASas of 30 Aug 202478.82k0.23%
SG 29 Haussmann SASUas of 07 Nov 202465.00k0.19%
More ▼
Data from 30 Jun 2024 - 07 Nov 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.